TL;DR:: A 2026 placebo-controlled pilot (n=22) found 10 weeks of low-dose tesamorelin did not shift ADAS-Cog scores versus placebo (p=0.985): a null result.
Tesamorelin Cognition Pilot: What a 22-Person Null Result Shows
What Did the 2026 Tesamorelin Cognition Pilot Test?
A small randomised pilot, listed in PubMed Central as PMC13316082, asked whether growth hormone-releasing hormone (GHRH) signalling alters cognition and brain connectivity in older adults.[1] It enrolled 22 adults whose cognition ranged from normal to mild cognitive impairment (MCI), and randomised them in a double-blind design to a low-dose tesamorelin regimen or placebo for 10 weeks.[1]
Tesamorelin is a GHRH analogue. As a licensed pharmaceutical (EGRIFTA) it is approved in the United States for a separate indication, reduction of excess abdominal fat in HIV-associated lipodystrophy.[2] The question here is therefore a mechanistic research question rather than a test of the licensed use, which is why the study is framed as a pilot: it estimates feasibility and effect size ahead of any larger trial.
Double-blind, placebo-controlled, 22 participants, 10 weeks. Cognitive outcomes included the ADAS-Cog total score and word recall; an exploratory analysis examined functional brain connectivity.[1]
Source: PubMed Central, PMC13316082. See the PMC record for authors, journal and issue details.
What Did the Cognitive Scores Show?
Neither cognitive measure separated the arms. On the ADAS-Cog total score, the placebo group changed by −1.4 points and the tesamorelin group by −1.5, a between-group P value of 0.985.[1] On word recall, the placebo arm changed by +0.1 and the GHRH arm by −0.3 (P = 0.347).[1]
| Measure | Placebo change | Tesamorelin change | P (between groups) |
|---|---|---|---|
| ADAS-Cog total | −1.4 | −1.5 | 0.985 |
| Word recall | +0.1 | −0.3 | 0.347 |
Read the null correctly. A P value near 1.0 in 22 people does not prove the absence of an effect. It shows that, at this sample size and duration, the trial could not distinguish tesamorelin from placebo on these instruments.
Why Does a Negative Pilot Matter for GHRH Research?
GHRH analogues attract interest in neuroscience because the GH/IGF-1 axis declines with age and IGF-1 receptors are expressed in the brain. That is a plausible mechanism, not an established one. Mechanistic plausibility has to survive controlled testing, and null pilots are how a field calibrates itself: they prevent small, positive and unreplicated findings from hardening into received wisdom.
For preclinical researchers the practical consequence is modest but useful. If a pharmaceutical-grade GHRH analogue given for ten weeks produced no measurable shift on a standard cognitive battery, in vitro and animal work on GHRH-receptor signalling in neural tissue should be framed as mechanism-finding, not as translational validation. Our tesamorelin research overview sets out the receptor and cAMP signalling background.
How Does It Compare With Earlier GHRH Cognition Work?
Earlier randomised work, notably a 2012 study by Baker and colleagues, reported differences in executive-function measures with GHRH treatment in older adults, and has been widely cited as support for the axis.[3] A separate phase II protocol examined tesamorelin and cognition in ageing HIV-infected adults (NCT02572323).[4] The 2026 pilot did not show a cognitive signal on its primary instruments, although it used different instruments, a shorter window and a small mixed-cognition sample, so the results are not directly comparable.
The honest synthesis is that the cognitive question remains open and under-powered. Compare this with the body-composition literature, where pooled randomised evidence is far deeper; see our write-up of the 2026 tesamorelin visceral-fat meta-analysis for that contrast.
What About the Brain-Connectivity Signal?
The authors also ran an exploratory machine-learning analysis of functional connectivity, which suggested treatment-related differences between groups.[1] Exploratory analyses in a 22-person sample are hypothesis-generating by construction: they carry a high risk of overfitting, no multiplicity guarantees, and no pre-specified threshold. They are a reason to design a larger, adequately powered, pre-registered study, not evidence of an effect.
What Should UK Researchers Take From This?
Three points. First, keep licensed pharmaceutical research and research-use reagents strictly separate: this pilot reports on a clinical-grade product under trial conditions and says nothing about reagent-grade material. Second, look for effect sizes and confidence intervals in small studies, not just P values. Third, treat connectivity signals from tiny samples as leads. For the legal framing of research-use supply, see are research peptides legal in the UK.
Velox Peptides supplies Tesamorelin strictly as an HPLC-verified in vitro research reagent, with batch documentation on request. Researchers following the incretin literature will also find our Retatrutide research-reagent listing and the October 2026 retatrutide evidence map relevant; we identified no new retatrutide trial readout in the past seven days.
Tesamorelin is referenced here for research-news context only. Where supplied by Velox Peptides, it is a research reagent, not a medicine, and has not been evaluated by the MHRA or FDA in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment. PubMed Central, 2026. PMC13316082
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357:2359-2370. nejm.org
- Baker LD, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults. Archives of Neurology. 2012.
- Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons. ClinicalTrials.gov NCT02572323
- Velox Peptides. Tesamorelin research overview; Tesamorelin visceral-fat meta-analysis.
Frequently Asked Questions
What did the 2026 tesamorelin cognition pilot find?
The double-blind, placebo-controlled pilot enrolled 22 adults whose cognition ranged from normal to mild cognitive impairment and compared a low-dose tesamorelin regimen with placebo over 10 weeks. ADAS-Cog total score changed by -1.4 in the placebo arm and -1.5 in the tesamorelin arm (between-group p = 0.985), so the primary cognitive measure showed no difference.
Does this null result say anything about tesamorelin's licensed use?
No. Tesamorelin (EGRIFTA) is FDA-approved for a different indication, excess abdominal fat in HIV-associated lipodystrophy. A negative cognition pilot in a small mixed-cognition cohort is a separate question and does not alter the licensed-product evidence base.
Why is a 22-participant pilot still worth reporting?
Pilots establish feasibility and effect-size estimates for larger studies, and null results prevent publication bias from inflating the apparent evidence for a mechanism. With only 22 participants, a null result cannot rule out a small effect; it narrows the plausible range.
Was the connectivity finding confirmatory?
No. The brain-connectivity differences came from an exploratory machine-learning analysis in a very small sample. They are hypothesis-generating only and should not be read as an efficacy signal.
Is Velox's research-use tesamorelin connected to this trial?
No. This article reports third-party clinical research on a pharmaceutical-grade GHRH analogue. Velox Peptides supplies tesamorelin strictly as an HPLC-verified in vitro research reagent, with no dosing guidance and no therapeutic claims.